title: [Systemic embolism after reversion to sinusal rhythm of persistent atrial flutter].
abstract: BACKGROUND
  The incidence of embolism in atrial flutter has been underestimated in the routine clinical practice.
  
  
  METHODS
  In this study the incidence of thromboembolic events after restoration of sinus rhythm (by catheter ablation or cardioversion) was compared in two groups of consecutive patients, with a different anticoagulation protocol. A total of 169 patients were evaluated. A first retrospective analysis of 79 non anticoagulated patients (group I). A second prospective group of 90 patients who were treated with an anticoagulation protocol (group II) similar to that for patients with atrial fibrillation. All had typical atrial flutter of at least one month's duration before the procedure.
  
  
  RESULTS
  The mean age of patients in group I was 61 12 years and the mean left ventricular ejection fraction was 57 6%. Patients in group II had a mean age of 61 10 years and the mean left ventricular ejection fraction was 56 9%. No differences were observed regarding prevalence of structural cardiopathy, arterial hypertension, diabetes mellitus, left ventricular dysfunction, atrial size or atrial fibrillation between the two groups of patients. Four patients in the retrospective analysis (5%) had an embolic event associated with the procedure, compared with 0 (0%) in the group of patients treated with the anticoagulation protocol. The efficient anticoagulation was associated with a lower risk of thromboembolic events (p < 0.05).
  
  
  CONCLUSIONS
  The incidence of embolic events after reversion to sinusal rhythm of persistent atrial flutter can be decreased. These patients should follow the same recommendations of anticoagulation that apply for patients with persistent atrial fibrillation that are going to be reverted to sinus rhythm.
authors.affiliation: Servicio de Cardiología. Unidad de Arritmias. Hospital Ramón y Cajal. Departamento de Medicina. Universidad de Alcalá de Henares. Madrid. Spain.
authors.forename: A
authors.initials: A
authors.lastname: Hernández Madrid
authors.forename: G
authors.initials: G
authors.lastname: Peña Pérez
authors.forename: J M
authors.initials: JM
authors.lastname: González Rebollo
authors.forename: M
authors.initials: M
authors.lastname: Gómez Bueno
authors.forename: I
authors.initials: I
authors.lastname: Marín Marín
authors.forename: E
authors.initials: E
authors.lastname: Bernal Morell
authors.forename: C
authors.initials: C
authors.lastname: Escobar Cervantes
authors.forename: A
authors.initials: A
authors.lastname: Camino López
authors.forename: J
authors.initials: J
authors.lastname: Peng
authors.forename: C
authors.initials: C
authors.lastname: Moro Serrano
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001282:Atrial Flutter / Q000150:complications*; D004554:Electric Countershock / Q000295:instrumentation*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D012804:Sick Sinus Syndrome / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000925:Anticoagulants